Italy Cancer Supportive Care Drugs Market Size & Outlook
Italy cancer supportive care drugs market, 2018-2030 (US$M)
Related Markets
Italy cancer supportive care drugs market highlights
- The Italy cancer supportive care drugs market generated a revenue of USD 634.7 million in 2023 and is expected to reach USD 571.4 million by 2030.
- The Italy market is expected to grow at a CAGR of -1.5% from 2024 to 2030.
- In terms of segment, opioids was the largest revenue generating therapeutic class in 2023.
- NSAIDs and Others is the most lucrative therapeutic class segment registering the fastest growth during the forecast period.
Cancer supportive care drugs market data book summary
| Market revenue in 2023 | USD 634.7 million |
| Market revenue in 2030 | USD 571.4 million |
| Growth rate | -1.5% (CAGR from 2023 to 2030) |
| Largest segment | Opioids |
| Fastest growing segment | NSAIDs and Others |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | G-CSFs (Granulocyte-colony Stimulating Factors), ESAs (Erythropoiesis Stimulating Agents), Antiemetics, Bisphosphonates, Opioids, NSAIDs and Others |
| Key market players worldwide | Amgen Inc, Merck & Co Inc, Johnson & Johnson, Heron Therapeutics Inc, Novartis AG ADR, GSK PLC, Roche Holding AG ADR, Helsinn Healthcare |
Other key industry trends
- In terms of revenue, Italy accounted for 4.8% of the global cancer supportive care drugs market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany cancer supportive care drugs market is projected to lead the regional market in terms of revenue in 2030.
- Russia is the fastest growing regional market in Europe and is projected to reach USD 305.1 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cancer Supportive Care Drugs Market Scope
Cancer Supportive Care Drugs Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Italy cancer supportive care drugs market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cancer supportive care drugs market will help companies and investors design strategic landscapes.
Opioids was the largest segment with a revenue share of 25.59% in 2023. Horizon Databook has segmented the Italy cancer supportive care drugs market based on g-csfs (granulocyte-colony stimulating factors), esas (erythropoiesis stimulating agents), antiemetics, bisphosphonates, opioids, nsaids and others covering the revenue growth of each sub-segment from 2018 to 2030.
In Italy, cancer pain prevalence varies depending upon the stage of cancer treatment; for patients after curative treatment, prevalence is around 33%, in patients with anticancer treatment, it is around 59%, and for patients at metastatic, advanced stage, it is around 64%. In addition, the percentage of cancer survivors who suffer from chronic severe pain is about 5%-10%.
Opioids, G-CSFs, NSAIDs, and antiemetics are among common drugs recommended for cancer supportive care in Italy. In Italy, strong opioids drugs such as methadone and morphine are completely covered under reimbursement. However, weak opioid drugs such as tramadol and codeine are not covered under reimbursement. Similarly, owing to the presence of several biosimilars, most of the cancer supportive care drugs are covered under reimbursement in Italy.
Reasons to subscribe to Italy cancer supportive care drugs market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Italy cancer supportive care drugs market databook
-
Our clientele includes a mix of cancer supportive care drugs market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Italy cancer supportive care drugs market , including forecasts for subscribers. This country databook contains high-level insights into Italy cancer supportive care drugs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Italy cancer supportive care drugs market size, by therapeutic class, 2018-2030 (US$M)
Italy Cancer Supportive Care Drugs Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
